Replies to post #83156 on Biotech Values

[genisi]

this acquisition gives ABT something to compete with Alcon’s Restor® product line

I see from Visiogen's ASCRS presentations that results from a multicenter, double-masked, randomized trial comparing Synchrony to the Alcon ReSTOR multifocal IOL, showed a stat-sig improvement in intermediate vision vs. ReSTOR, improved spectacle independence, and equivalent near and distance vision at twelve months. Also, data demonstrated low rates of posterior capsular opacification (PCO), in a population of 209 patients at two years. I guess that's part of why ABT is paying $400M.